ALK and mature T-cell and NK-cell non-Hodgkin lymphoma: Using an arbitrary 10% cutoff, STING was positive in 36 out of 38 (95%) cases of ALK+ ALCL, 23 out of 37 (62%) ALK-ALCL, 3 out of 3 (100%) breast implant-associated (BIA) ALCL, 1 out of 13 (7.7%) AITL, 15 out of 19 (79%) PTCL-NOS, 0 out of 1 (0%) MEITL, 20 out of 36 (56%) NK/T-nasal type, 6 out of 7 (86%) T-LBL, and 3 out of 4 (75%) MF cases (Figure 3).